Sanofi and Selecta partner to develop new immunotherapy for celiac disease

French drugmaker Sanofi has exercised its option with Selecta Biosciences for second exclusive licence to develop an immunotherapy to treat celiac disease.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news